Orazol™ (MER-101)

Orazol™ is in Phase II development for the treatment of Bone Metastases associated with solid tumours.

Orazol™ is a bisphosphonate (zoledronic acid) compound for metastatic bone disease. Because of poor bioavailability, the bisphosphonate products available and indicated for oncology indications are usually administered by intravenous infusion. The sales of zoledronic acid as an intravenous infusion were $1.3Bn in 2007.

Merrion uses GIPET® technology to formulate a sufficiently bioavailable oral dosage form of the market leading bisphosphonate for bone metastases.

Having an orally available product brings several benefits over current infusion techniques:

More convenient for patients
Reduction in the administration costs of the drug
Avoiding the risks of breaking the skin
May allow additional patient populations access to the medication due to the simpler administration and the lower overall cost of administration

The proof of principle for a weekly oral formulation has been demonstrated in a patient population clinical study.

Clinical Data for Orazol™ final Phase II Study was presented at ASCO, American Society of Clinical Oncology Annual Meeting, 2009, Orlando, Florida

For more information or to view a copy of the poster, please click here

< back